ASH 2018: Best Kept Secret at ASH in Multiple Myeloma

 

Pieter Sonneveld, Professor of Hematology and head of the Department of Hematology at the Erasmus MC Cancer Institute and Professor of Hematology at the Erasmus University of Rotterdam, The Netherlands presented the early findings of the study.  This Phase 2 trial was designed for patients with refractory disease or first progression in order to evaluate a salvage treatment with next generation proteasome inhibition and immunomodulators, i.e., Carfilzomib, Pomalidomide and Dexamethasone. The primary endpoints were response and progression-free survival (PFS).

 

• Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma - ORR of 48%
• Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study - ORR of 33%
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial - ORR of 29.2%
• Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase I/II open-label, dose escalation study - ORR of 52%
• PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma - ORR of 34%